sprycel
bristol-myers squibb pharma eeig - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - sprycel je primerna za zdravljenje pediatričnih bolnikov z:novo diagnosticiranih philadelphia kromosom-pozitivno kronične myelogenous levkemijo v kronično fazo (ph+ cml kt) ali ph+ cml cp odporne ali nestrpni, da pred terapijo, vključno z imatinib. na novo diagnosticirana ph+ acute lymphoblastic levkemijo (all) v kombinaciji s kemoterapijo. sprycel je indiciran za zdravljenje odraslih bolnikov z:novo diagnosticiranih philadelphia-kromosoma-pozitivne (ph+) kronična myelogenous levkemijo (cml) v kronično fazo;kronično, pospešeno ali pišu faze cml s odpornost ali nestrpnosti predhodno zdravljenje, vključno z imatinib mesilate;ph+ acute lymphoblastic levkemijo (all) in lymphoid pišu cml s odpornost ali nestrpnosti do pred terapijo. sprycel je primerna za zdravljenje pediatričnih bolnikov z:novo diagnosticirana ph+ cml v kronično fazo (ph+ cml-cp) ali ph+ cml-cp odporne ali nestrpni, da pred terapijo, vključno z imatinib.
dasatinib krka 100 mg filmsko obložene tablete
dasatinib - filmsko obložena tableta - dasatinib 100 mg / 1 tableta - dasatinib
dasatinib krka 50 mg filmsko obložene tablete
dasatinib - filmsko obložena tableta - dasatinib 50 mg / 1 tableta - dasatinib
dasatinib krka 70 mg filmsko obložene tablete
dasatinib - filmsko obložena tableta - dasatinib 70 mg / 1 tableta - dasatinib
dasatinib krka 20 mg filmsko obložene tablete
dasatinib - filmsko obložena tableta - dasatinib 20 mg / 1 tableta - dasatinib
dasatinib teva 100 mg filmsko obložene tablete
dasatinib - filmsko obložena tableta - dasatinib 100 mg / 1 tableta - dasatinib
dasatinib teva 50 mg filmsko obložene tablete
dasatinib - filmsko obložena tableta - dasatinib 50 mg / 1 tableta - dasatinib
dasatinib teva 70 mg filmsko obložene tablete
dasatinib - filmsko obložena tableta - dasatinib 70 mg / 1 tableta - dasatinib
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.